Tag: capacity

PITTSBURGH, Pa., June 18, 2026 (GLOBE NEWSWIRE) -- Eos Energy Enterprises, Inc. (NASDAQ: EOSE) (“Eos” or the “Company”), America’s leading innovator in designing, manufacturing, and providing zinc-based long-duration energy storage (LDES) systems sourced and manufactured in the United States, today announced the first purchase order under the 2 GWh capacity reservation agreement with Frontier Power USA Parent, LLC (FPUSA). The order supports FPUSA’s Redbird project, a 100 MW / 400 MWh battery energy storage system using Eos’ Z3™ technology.

Malibu, California, June 18, 2026 (GLOBE NEWSWIRE) -- Trio Petroleum Corp ("Trio" or the "Company") (NYSE American: TPET) is pleased to provide shareholders with an update regarding its acquisition strategy and ongoing efforts to build a diversified portfolio of cash-flowing oil and gas assets.

Under a Contemplated Master LOI Between BlueFlare and Bloc3 Energy LLC, in Partnership with ZAJA LLC, ROMA Would Be Granted a Non-Exclusive Right of First Offer on Site-Level Financing Across a Portfolio of 1- to 10-MW BTM Data Centres Targeting Up to 500 MW in Alberta

Creates a scaled BDC positioned for growth while maintaining industry leading credit quality and portfolio yield

(Oslo/Lista, Norway 18 June 2026) Statkraft and Alcoa have signed two new power agreements securing electricity supply to support continued operation of Alcoa’s aluminium plant at Lista, Norway. The agreements provide a solid and predictable energy foundation for the smelter and help maintain both production and further development at the site.

Production Line 2 at Lista recently completed a successful restart of 31,000 metric tonnes per annum to reach its nameplate capacity of 95,000 metric tonnes for the plant. This marked an important milestone for Alcoa in Norway, with restored capacity and a strengthened industrial presence. Building on this, access to reliable and competitively priced power is essential for continued operations.

MANCHESTER, United Kingdom and OSAKA, Japan, June 18, 2026 (GLOBE NEWSWIRE) -- F2G Ltd and Shionogi & Co., Ltd (Head Office: Osaka, Japan; Chief Executive Officer: Isao Teshirogi, Ph.D) (“Shionogi”) today announced positive topline results from the global Phase 3 OASIS study (NCT05101187), comparing the investigational oral antifungal drug olorofim versus AmBisome® (liposomal amphotericin B for injection) followed by standard of care (SOC) in patients with invasive aspergillosis whose infection is either refractory to or unsuitable for azole therapy.